{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:08:04Z","timestamp":1790809684856,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1136\/ijgc-2019-001135","type":"journal-article","created":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T13:55:13Z","timestamp":1590242113000},"page":"1065-1070","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study"],"prefix":"10.1016","volume":"30","clinical-trial-number":[{"clinical-trial-number":"nct03830866","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02125461","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03830866","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jyoti","family":"Mayadev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana T","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Marcovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C","family":"Lanasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2019-001135_bb0010","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0140-6736(01)05965-7","article-title":"Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis","volume":"358","author":"Green","year":"2001","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2019-001135_bb0015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1586\/14737140.2016.1121108","article-title":"Immunotherapy and targeted therapy for cervical cancer: an update","volume":"16","author":"Menderes","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1136\/ijgc-2019-001135_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00689","article-title":"Cervical cancer neoantigen landscape and immune activity is associated with human papillomavirus master regulators","volume":"8","author":"Qin","year":"2017","journal-title":"Front Immunol"},{"key":"10.1136\/ijgc-2019-001135_bb0025","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1111\/jog.13411","article-title":"Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status","volume":"43","author":"Yang","year":"2017","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1136\/ijgc-2019-001135_bb0030","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/modpathol.2016.221","article-title":"Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer","volume":"30","author":"Enwere","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1136\/ijgc-2019-001135_bb0035","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.5514","article-title":"Pembrolizumab for previously treated advanced cervical squamous cell cancer: preliminary results from the phase 2 KEYNOTE-158 study","volume":"35","author":"Schellens","year":"2017","journal-title":"JCO"},{"key":"10.1136\/ijgc-2019-001135_bb0040","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2019-001135_bb0045","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/COC.0b013e31819142dc","article-title":"Prognostic significance of histology and positive lymph node involvement following radical hysterectomy in carcinoma of the cervix","volume":"32","author":"Macdonald","year":"2009","journal-title":"Am J Clin Oncol"},{"key":"10.1136\/ijgc-2019-001135_bb0050","unstructured":"Surveillance, Epidemiology, and End Results (SEER) . Seer is an authoritative source for cancer statistics in the United States. Available: www.seer.cancer.gov [Accessed 11 Nov 2019]."},{"key":"10.1136\/ijgc-2019-001135_bb0055","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS5597","article-title":"CALLA: efficacy and safety of durvalumab with and following concurrent chemoradiotherapy (CCRT) versus CCRT alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study","volume":"37","author":"Monk","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2019-001135_bb0060","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.8511","article-title":"Prospective phase I multi-institutional trial of PD-1 blockade with pembrolizumab during concurrent chemoradiation for locally advanced, unresectable non-small cell lung cancer","volume":"37","author":"Jabbour","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2019-001135_bb0065","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2019-001135_bb0070","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1200\/JCO.2016.66.9861","article-title":"Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","author":"Rizvi","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24001786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24001786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2019-001135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:25:18Z","timestamp":1753233918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24001786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1048891X24001786"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2019-001135","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2019-001135","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/.","name":"copyright","label":"Copyright"}]}}